AUROPHARMA financials

Chart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹9,150cr+16.3% on Q1 FY26
Net profit
₹1,032cr+25.2% on Q1 FY26
EBITDA margin
20.6%+0.2 pts on Q1 FY26
EPS
₹17.86+25.8% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue9,1507,868+16.3%
EBITDA1,8811,603+17.3%
EBITDA margin20.6%20.4%+0.2 pts
Profit before tax1,5171,205+25.9%
Net profit1,032824+25.2%
EPS₹17.86₹14.20+25.8%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹9,150 crNet profit₹1,032 crNet margin11.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
95,530————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
7,9397,9395,5693,4444,547
−8.2−8.2−6.48.012.0
7,6767,6767,9426,3154,862
95,259————
34,93533,65331,72429,00224,855
—+6.1%+9.4%+16.7%—
7,0856,8466,5835,8433,719
20.3%20.3%20.8%20.2%15.0%
5,2265,0684,9334,3212,474
3,7113,5033,4843,1691,928
10.6%10.4%11.0%10.9%7.8%
₹63.92₹60.34₹60.02₹54.63₹33.19
—+0.5%+9.9%+64.6%—
—5,5263,9252,4352,387
—−3,105−2,520−3,562−2,720
2,4222,4221,405−1,127−334
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AUROPHARMA₹1,644.80

AUROPHARMA

₹ CroreMcap ₹95,530 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————95,530.0
- Cash, Equiv & ST Investments4,547.33,444.15,569.07,938.67,938.6
+ Minority Interest12.08.0-6.4-8.2-8.2
+ Total Debt4,861.56,315.27,941.77,676.27,676.2
Enterprise Value————95,259.4
Revenue24,855.429,001.931,723.733,653.134,935.3
Growth %, YoY—+16.7+9.4+6.1—
EBITDA3,718.65,843.06,582.86,845.77,085.3
Margin %14.9620.1520.7520.3420.28
EBIT2,474.14,321.34,933.45,067.55,226.0
Net Income1,927.73,169.03,483.63,503.03,710.8
Margin %7.7610.9310.9810.4110.62
EPS, Adj (current shares)33.1954.6360.0260.3463.92
Growth %, YoY—+64.6+9.9+0.5—
Cash from Operations2,386.82,434.53,924.65,526.4—
Capital Expenditures-2,720.4-3,561.5-2,519.6-3,104.7—
Free Cash Flow-333.7-1,127.01,405.12,421.72,421.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Aurobindo Pharma financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Aurobindo Pharma (NSE: AUROPHARMA) had a market capitalisation of ₹95,511 crore at the 29 October 2026 close (₹1,659.90 a share), a PE ratio of 25.7 on the last four quarters' profit and a price-to-book ratio of 2.52. In FY26 its consolidated net profit attributable to shareholders was ₹3,505 crore on revenue of ₹33,653 crore; in Q1 FY27 (April–June 2026) it was ₹1,033 crore, up 25.2% year on year. Its debt-to-equity ratio was 0.20 on 31 March 2026.

Share price used
₹1,659.90 · 29 October 2026 close
Latest balance sheet
31 March 2026

Aurobindo Pharma at a glance · consolidated

Market cap
₹95,511 Crat ₹1,659.90 · 29 Oct close
PE ratio (last 4 quarters)
25.727.3 on FY26 profit
Price to book (PB)
2.52book value ₹658.52 a share
ROE (FY26)
9.9%−1.2 pts vs FY25ROCE 13.4%
Debt to equity
0.20net cash ₹2,941 Cr
Net worth
₹37,891 Cr+16.0% vs 31 Mar 202531 March 2026

Questions

What is the Aurobindo Pharma PE ratio today?

Aurobindo Pharma's PE ratio is 25.7 at the 29 October 2026 close (₹1,659.90 a share): a market capitalisation of ₹95,511 crore divided by consolidated net profit attributable to shareholders of ₹3,713 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹3,505 crore) it is 27.3.

What is the Aurobindo Pharma PB ratio (price to book value)?

Aurobindo Pharma's price-to-book (PB) ratio is 2.52 at the 29 October 2026 close: a market capitalisation of ₹95,511 crore divided by shareholders' equity (book value) of ₹37,891 crore on 31 March 2026. That is a book value of ₹658.52 per share against a share price of ₹1,659.90.

What is the Aurobindo Pharma ROE and ROCE?

In FY26, Aurobindo Pharma's return on equity (ROE) was 9.9% and its return on capital employed (ROCE) was 13.4%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.2% and ROCE 14.5%.

What is the Aurobindo Pharma market cap?

Aurobindo Pharma's market capitalisation was ₹95,511 crore at the 29 October 2026 close: 57.54 crore shares at ₹1,659.90 each.

Is Aurobindo Pharma debt free?

No. Aurobindo Pharma had borrowings of ₹7,676 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.20. Its cash and current investments were ₹10,618 crore, so it held net cash of ₹2,941 crore.

What is the Aurobindo Pharma EPS?

Aurobindo Pharma's basic earnings per share (EPS) were ₹60.34 in FY26, against ₹59.81 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹64.00.

What is the Aurobindo Pharma debt to equity ratio?

Aurobindo Pharma's debt-to-equity ratio was 0.20 on 31 March 2026: borrowings of ₹7,676 crore against total equity of ₹37,883 crore. A year earlier, on 31 March 2025, it was 0.24.

What is the Aurobindo Pharma net worth?

Aurobindo Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹37,891 crore on 31 March 2026, up 16.0% from ₹32,653 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹95,511 crore at the 29 October 2026 close.

What is the Aurobindo Pharma free cash flow?

In FY26, Aurobindo Pharma generated ₹5,526 crore of cash from operations and spent ₹3,105 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹2,422 crore. In FY25 it was ₹1,405 crore.

What is the Aurobindo Pharma book value per share?

Aurobindo Pharma's book value per share was ₹658.52 on 31 March 2026: shareholders' equity of ₹37,891 crore divided by the 57.54 crore shares in issue, up 17.1% from ₹562.21 a year earlier. The share price at the 29 October 2026 close was ₹1,659.90.

What are the Aurobindo Pharma latest quarterly results?

Aurobindo Pharma's latest results are for Q1 FY27 (April–June 2026), filed on 5 August 2026: consolidated net profit attributable to shareholders ₹1,033 crore, up 25.2% from ₹825 crore in Q1 FY26; revenue from operations ₹9,150 crore, up 16.3% year on year.

What is the Aurobindo Pharma revenue and profit in FY26?

In FY26 (April 2025–March 2026), Aurobindo Pharma's consolidated net profit attributable to shareholders was ₹3,505 crore, up 0.5% from ₹3,486 crore in FY25, on revenue from operations of ₹33,653 crore (up 6.1%). Over three years, from FY23, net profit was up 81.8%.

When are the Aurobindo Pharma next results?

Aurobindo Pharma will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.

Where do these Aurobindo Pharma figures come from?

From Aurobindo Pharma's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.